{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:12:39Z","timestamp":1790946759054,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":389,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2000,12]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Although there is little information from primary or secondary prevention trials on cholesterol\u2010lowering medication in diabetic patients, the reduction of elevated cholesterol is widely recommended for this group. The American Diabetes Association (ADA) recommends drug therapy in diabetic patients if low density lipoprotein (LDL)\u2010cholesterol remains at &gt;\u200a130\u2003mg\/dl, or\u2003&gt;\u2003100\u2003mg\/dl in patients with macroangiopathy, after dietary intervention. When cholesterol\u2010lowering medication is indicated, the choice of the drug must take into account the other lipid abnormalities that are often present and the need to maintain optimal glycaemic control. In the present study we compared the efficacy and safety of the novel HMG\u2010CoA reductase inhibitor atorvastatin at the dose of 10\u2003mg\/day with simvastatin , lovastatin and pravastatin at doses of 10, 20 and 20\u2003mg\/day, respectively, and placebo, in type 2 diabetic patients with moderate elevation of LDL\u2010cholesterol with or without elevation of triglycerides. All the quoted agents are enzyme inhibitors effective in lowering LDL\u2010cholesterol in humans. The efficacy endpoints were the mean per cent changes in plasma LDL\u2010cholesterol (primary), total cholesterol, triglycerides, and high\u2010density lipoprotein (HDL)\u2010cholesterol concentrations from baseline to the end of treatment (24\u2003weeks). Atorvastatin at a dose of 10\u2003mg\/day produced: (1) a significant reduction in LDL\u2010cholesterol (\u2212\u200337%) in comparison with equivalent doses of simvastatin<\/jats:p>\n                  <jats:p>(\u2212\u200326%), pravastatin (\u2212\u200323%), lovastatin (\u2212\u200321%), and placebo (\u2212\u20031%); (2) HDL\u2010cholesterol increases (7.4%) comparable to or greater than those obtained with simvastatin (7.1%), pravastatin (3.2%), lovastatin (7.21%), and placebo (\u2212\u20030.5%); (3) a significantly greater reduction in total cholesterol (\u2212\u200329%) than that obtained with simvastatin (\u2212\u200321%), pravastain (\u2212\u200316%), lovastatin (\u2212\u200318%), and placebo (1%); and (4) a significantly greater reduction in triglycerides than that obtained with all the other drugs and placebo. In all treatment groups no significant variation in fibrinogen concentration was observed. All reductase inhibitors studied had similar levels of tolerance. There were no incidents of persistent elevations of serum aminotransferases or myositis.<\/jats:p>","DOI":"10.1046\/j.1463-1326.2000.00106.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T09:59:24Z","timestamp":1047376764000},"page":"355-362","source":"Crossref","is-referenced-by-count":45,"title":["Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia"],"prefix":"10.1111","volume":"2","author":[{"given":"S.","family":"Gentile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Guarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. F.","family":"Sasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Amodio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Magliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Corigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Agrusta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Gaeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Oliviero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Torella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.59.1.8"},{"key":"e_1_2_6_3_2","first-page":"21","article-title":"The Whitehall Study: comparative mortality rates and indices of risk in diabetes","volume":"110","author":"Jarrett RJ","year":"1985","journal-title":"Acta Endocrinol"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.6.4.361"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.299.6708.1127"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.16.2.434"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.130.6.833"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00265546"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6117.883"},{"key":"e_1_2_6_10_2","first-page":"836","article-title":"Association of low HDL and LDL2 cholesterol with coronary heart disease in non\u2010insulin\u2010dependent diabetics","volume":"28","author":"Laasko M","year":"1979","journal-title":"Diabetes"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00276969"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-87-4-393"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.31.2.126"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113348"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.CIR.85.1.37","article-title":"Serum lipids and lipoproteins in newly diagnosed non\u2010insulin\u2010dependent (type II) diabetic patients, with special reference to factors influencing HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment","volume":"85","author":"Uusitupa M","year":"1992","journal-title":"Circulation"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.85.1.37"},{"key":"e_1_2_6_17_2","first-page":"19","volume-title":"In Assmann G","author":"Assmann G","year":"1993"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2337\/diacare.16.5.828","article-title":"Clinical practice recommendations. Detection and management of lipid disorder in diabetes (Consensus Statement)","volume":"16","author":"American Diabetes Association.","year":"1993","journal-title":"Diabetes Care"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03500230097036"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(97)00965-x"},{"key":"e_1_2_6_21_2","first-page":"S19","article-title":"Detection and management of lipid disorders in Diabetes","volume":"19","author":"ADA Consensus Statement.","year":"1996","journal-title":"Diabetes Care"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.44.4.460"},{"key":"e_1_2_6_23_2","first-page":"74","article-title":"Atorvastatin and simvastatin reduce elevated cholesterol in non\u2010insulin dependent diabetes","volume":"9","author":"Best JB","year":"1996","journal-title":"Diab Nutr Metab"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.13.2.153"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9150(97)88653-4"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(94)90198-8"},{"key":"e_1_2_6_27_2","first-page":"499","article-title":"Estimation of the concentration of ultracentrifuge","volume":"18","author":"Friedewald WT","year":"1972","journal-title":"Clin Chem"},{"key":"e_1_2_6_28_2","first-page":"850","article-title":"Standardization of micromethods for plasma cholesterol, triglyceride and HDL\u2010cholesterol with the Lipid Research Clinics' methodology","volume":"19","author":"Steiner PM","year":"1981","journal-title":"J Clin Chem Biochem"},{"key":"e_1_2_6_29_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/clinchem\/22.1.98","article-title":"Enzymatic determinations of cholesterol in high density lipoprotein fractions prepared by a precipitation technique","volume":"22","author":"Steele WB","year":"1976","journal-title":"Clin Chem"},{"key":"e_1_2_6_30_2","first-page":"261","article-title":"Measurement of protein with the Boehringg nephelometer: a multicenter evaluation","volume":"27","author":"Fink PC","year":"1989","journal-title":"J Clin Chem Clin Biochem"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1955.10501294"},{"key":"e_1_2_6_32_2","doi-asserted-by":"crossref","unstructured":"Blum C.Comparison of properties of four inhibitors of 3\u2010hydrozyl\u20103\u2010methylglutaryl\u2010coenzume A reductase. Am J Cardiol.; 73: 3D\u201011D. 1994.","DOI":"10.1016\/0002-9149(94)90626-2"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90692-9"},{"key":"e_1_2_6_34_2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2337\/diab.38.5.562","article-title":"Increased \u03b2\u2010cell secretory capacity as mechanism for islet adaptation to nicotinic acid\u2010induced resistance","volume":"38","author":"Kahn SE","year":"1989","journal-title":"Diabetes"},{"key":"e_1_2_6_35_2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jama.1990.03450060069031","article-title":"Nicotinic acid as therapy for dyslipidemia in NIDDM","volume":"264","author":"Garg A","year":"1990","journal-title":"JAMA"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198801143180204"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.38.3.364"},{"key":"e_1_2_6_38_2","first-page":"10021","article-title":"Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mol\/liter (200\u2013399 mg\/dl) plus two additional atherosclerotic risk factors","volume":"72","author":"The Pravastatin Multinational Study Group for Cardiac Risk Patients.","year":"1993","journal-title":"Am J Cardiol"},{"key":"e_1_2_6_39_2","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, the Scandinavian Simvastatin Survey Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group.","year":"1994","journal-title":"Lancet"},{"key":"e_1_2_6_40_2","first-page":"734","article-title":"Comparative evaluation of the safety and efficacy of HMG\u2010CoA reductase inhibitor monotherapy in treatment of primary hypercholesterolemia","volume":"29","author":"Usu I","year":"1995","journal-title":"Ann Pharmacother"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90053-Z"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2760(92)90103-3"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.15.5.678"},{"key":"e_1_2_6_44_2","unstructured":"Gmerek A Yang R Bays Het\u00a0al.Atorvastatin causes a dose\u2010dependent reduction in LDL\u2010C and triglycerides. In:Black D ed.The Sixty\u2010Sixth Congress of European Artherosclerosis Society.Paris 1996212. July 1996."},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(97)00174-4"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(95)05757-9"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649476"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)78556-1"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9150(96)06052-2"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(97)00280-4"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351401"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1463-1326.2000.00106.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1046\/j.1463-1326.2000.00106.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:29Z","timestamp":1761870149000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1046\/j.1463-1326.2000.00106.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["10.1046\/j.1463-1326.2000.00106.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1463-1326.2000.00106.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}